- Report
- March 2024
- 181 Pages
Global
From €3241EUR$3,374USD£2,790GBP
€3601EUR$3,749USD£3,100GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1441EUR$1,500USD£1,240GBP
- Report
- December 2023
- 157 Pages
Global
€4798EUR$4,995USD£4,130GBP
- Report
- August 2022
- 120 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- March 2018
- 17 Pages
Global
From €9605EUR$10,000USD£8,269GBP
- Report
- March 2019
- 195 Pages
Global
From €10560EUR$10,995USD£9,092GBP
- Report
- May 2020
- 173 Pages
Global
From €3458EUR$3,600USD£2,977GBP
- Report
- September 2019
- 70 Pages
Global
From €3122EUR$3,250USD£2,687GBP
- Drug Pipelines
- June 2021
- 90 Pages
Global
From €1921EUR$2,000USD£1,654GBP
Romosozumab is a monoclonal antibody used to treat osteoporosis and other musculoskeletal disorders. It works by inhibiting the activity of sclerostin, a protein that inhibits bone formation. This allows for increased bone formation and improved bone mineral density. It is administered as a subcutaneous injection once a month.
Romosozumab is a relatively new drug, having been approved by the US Food and Drug Administration in April 2017. It is the first monoclonal antibody approved for the treatment of osteoporosis. It is also being studied for the treatment of other musculoskeletal disorders, such as Paget's disease and osteogenesis imperfecta.
Romosozumab is marketed by Amgen, UCB, and Radius Health. Amgen markets the drug under the brand name Evenity, while UCB markets it under the brand name Tymlos. Radius Health markets the drug under the brand name Preos. Show Less Read more
